Antiapoptotic BCL-2 is required for maintenance of a model leukemia

Cancer Cell. 2004 Sep;6(3):241-9. doi: 10.1016/j.ccr.2004.07.011.


Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required in the genesis of cancer. However, it remains uncertain whether apoptotic defects are essential for tumor maintenance. To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic leukemia. Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating BCL-2 as a rational target for cancer therapy. Loss of this single molecule resulted in cell death, despite or perhaps attributable to the presence of other oncogenic events. This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Apoptosis
  • Cytochromes c / metabolism
  • Doxycycline / pharmacology
  • Genes, bcl-2*
  • Genes, myc
  • Humans
  • Leukemia, B-Cell / genetics
  • Leukemia, Lymphoid / genetics*
  • Mice
  • Mice, Transgenic
  • Mitochondria / metabolism
  • Neoplasm Transplantation
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-bcl-2*
  • Tumor Cells, Cultured
  • bcl-2-Associated X Protein


  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-2-Associated X Protein
  • Cytochromes c
  • Doxycycline